Plain-English translation of NCT06776757 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called sintilimab combined with two other cancer treatments (cetuximab and chemotherapy) in people with advanced colorectal cancer that has spread to other parts of the body. Sintilimab is designed to help your immune system recognize and attack cancer cells more effectively. The study will first find the right dose of this medication to use safely, then test how well the combination works for treating this type of cancer.
Current first-line treatments for advanced colorectal cancer help people live about 20โ30 months on average, but doctors believe better options are needed. Research suggests that this medication could work together with cetuximab and chemotherapy to activate your immune system in ways that might improve outcomes and help the treatment work better.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
In this trial, you would receive the new medication (sintilimab) combined with cetuximab and chemotherapy, likely through intravenous infusions during regular clinic visits. The first phase involves finding the safest and most effective dose, and the second phase expands treatment to more patients. You would have regular blood tests and scans to monitor how well the treatment is working and to watch for side effects. The total duration and visit schedule will be explained to you in detail before you enroll.
AI-generated summary from trial data ยท Jun 30, 2026 ยท Not medical advice
China